KALA BIO, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from KALA BIO, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 2.1 times its market value (net cash). Higher than 96% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 1,532% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 91% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-107.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 82% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -89%In 3 years sales changed by -100% while total assets changed by -89%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
2.1× cashCash, after subtracting all debt, is 2.1 times its market value (net cash).
Higher than 96% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
KALA BIO, Inc. made a loss over the last year. KALA BIO, Inc. owes $0.15 for every $1 it owns. KALA BIO, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossKALA BIO, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.40The share price is 0.40 times KALA BIO, Inc.'s book value per share, lower than 93% of Healthcare companies in United States.
Market cap
$4 MThe total market value of all of KALA BIO, Inc.'s shares at today's price (share price × number of shares), smaller than 95% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$9 MWhat KALA BIO, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.47Net worth divided by the number of shares. The share price of $0.19 is 0.4 times this, which is the P/B above.
Return on equity (ROE)
-345.3%KALA BIO, Inc. lost 345.3% of its shareholders' money over the last year, lower than 90% of Healthcare companies in United States.
Owes vs Owns
0.15×KALA BIO, Inc. owes $0.15 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Dividend yield
NoneKALA BIO, Inc. does not currently pay a dividend.
Profit growth
LossKALA BIO, Inc. made a loss in each of the last two years.
Interest cover
Not coveredKALA BIO, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashKALA BIO, Inc. held $8 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For KALA BIO, Inc.: $4 M ÷ $9 M (30 Jun 2026) = 0.4.
What is KALA BIO, Inc.'s return on equity?
KALA BIO, Inc. lost 345.3% of its shareholders' money over the last year, lower than 90% of Healthcare companies in United States.
How much does KALA BIO, Inc. owe compared with what it owns?
KALA BIO, Inc. owes $0.15 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Does KALA BIO, Inc. pay a dividend?
No. KALA BIO, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.